WuXi Biologics (Cayman) Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 2/6

WuXi Biologics (Cayman) yıllık ortalama 23.7% oranında kazançlarını artırırken, Life Sciences sektöründe kazançlar growing at 13.9% annual. Gelirler growing yılda ortalama 32.7% oranında artmaktadır. WuXi Biologics (Cayman)'in özkaynak karlılığı 6.7% ve net marjı 15.4%'dir.

Anahtar bilgiler

23.7%

Kazanç büyüme oranı

22.3%

EPS büyüme oranı

Life Sciences Sektör Büyümesi	26.8%
Gelir büyüme oranı	32.7%
Özkaynak getirisi	6.7%
Net Marj	15.4%
Son Kazanç Güncellemesi	30 Jun 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Gelir ve Gider Dağılımı

WuXi Biologics (Cayman) nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

DB:1FW2 Gelir, gider ve kazançlar (CNY Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri	Ar-Ge Giderleri
30 Jun 24	17,116	2,632	2,356	788
31 Mar 24	17,075	3,016	2,221	787
31 Dec 23	17,034	3,400	2,086	786
30 Sep 23	16,794	3,776	2,021	769
30 Jun 23	16,554	4,152	1,956	753
31 Mar 23	15,911	4,286	1,824	718
31 Dec 22	15,269	4,420	1,693	683
30 Sep 22	14,179	4,251	1,472	670
30 Jun 22	13,090	4,081	1,251	657
31 Mar 22	11,690	3,735	1,192	579
31 Dec 21	10,290	3,388	1,133	502
30 Sep 21	9,183	3,092	1,043	398
30 Jun 21	8,075	2,795	952	295
31 Mar 21	6,844	2,242	837	299
31 Dec 20	5,612	1,689	722	304
30 Sep 20	4,967	1,494	648	289
30 Jun 20	4,321	1,300	574	275
31 Mar 20	4,152	1,157	512	267
31 Dec 19	3,984	1,014	451	260
30 Sep 19	3,535	922	427	241
30 Jun 19	3,087	831	404	222
31 Mar 19	2,811	731	365	196
31 Dec 18	2,534	631	326	169
30 Sep 18	2,277	520	270	132
30 Jun 18	2,019	410	214	94
31 Mar 18	1,819	331	195	84
31 Dec 17	1,619	253	175	74
30 Sep 17	1,429	177	155	66
30 Jun 17	1,233	149	128	60
31 Mar 17	1,111	145	119	56
31 Dec 16	989	141	110	53
30 Sep 16	889	171	101	61
31 Dec 15	557	45	86	40
31 Dec 14	332	42	48	35

Kaliteli Kazançlar: 1FW2 yüksek kaliteli kazançlar sağlıyor.

Büyüyen Kar Marjı: 1FW2 'nin mevcut net kar marjları (15.4%) geçen yılın (25.1%) değerinden daha düşüktür.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: 1FW2 şirketinin kazançları son 5 yılda yılda 23.7% oranında önemli ölçüde arttı.

Büyüme Hızlandırma: 1FW2 'in son bir yıldır negatif kazanç büyümesi oldu, bu nedenle 5 yıllık ortalamasıyla karşılaştırılamaz.

Kazançlar vs. Sektör: 1FW2 geçtiğimiz yıl negatif kazanç büyümesine ( -36.6% ) sahipti ve bu da onu Life Sciences sektör ortalamasıyla ( 5.4% ) karşılaştırmayı zorlaştırıyordu.

Özkaynak Getirisi

Yüksek ROE: 1FW2 'nin Özsermaye Getirisi ( 6.7% ) düşük olarak değerlendiriliyor.

WuXi Biologics (Cayman) Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 2/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

First half 2024 earnings released: EPS: CN¥0.36 (vs CN¥0.55 in 1H 2023)

First half 2024 earnings released: EPS: CN¥0.36 (vs CN¥0.55 in 1H 2023)

WuXi Biologics (Cayman) Inc. to Report First Half, 2024 Results on Aug 21, 2024

Full year 2023 earnings released: EPS: CN¥0.82 (vs CN¥1.06 in FY 2022)

Full year 2023 earnings released: EPS: CN¥0.82 (vs CN¥1.06 in FY 2022)

WuXi Biologics (Cayman) Inc. to Report Q4, 2023 Results on Mar 26, 2024

Recent updates

WuXi Biologics (Cayman) Inc. (SEHK:2269) completed the acquisition of remaining 30% stake in WuXi Vaccines (Cayman) Inc. from Shanghai Hile Bio-Technology Co., Ltd. (SHSE:603718).

Investor sentiment deteriorates as stock falls 22%

WuXi Reportedly Explores Sale of Pharma Units as US Restrictions Loom

First half 2024 earnings released: EPS: CN¥0.36 (vs CN¥0.55 in 1H 2023)

Investor sentiment improves as stock rises 17%

WuXi Biologics Successfully Completes First Scale-Up of High-Productivity Bioprocessing Platform WuXiUI in 2,000L GMP Manufacturing

First half 2024 earnings released: EPS: CN¥0.36 (vs CN¥0.55 in 1H 2023)

WuXi Biologics (Cayman) Inc. to Report First Half, 2024 Results on Aug 21, 2024

CEO & Executive Director recently sold €784k worth of stock

Investor sentiment deteriorates as stock falls 20%

Full year 2023 earnings released: EPS: CN¥0.82 (vs CN¥1.06 in FY 2022)

Less than half of directors are independent

WuXi Biologics (Cayman) Inc., Annual General Meeting, Jun 19, 2024

Full year 2023 earnings released: EPS: CN¥0.82 (vs CN¥1.06 in FY 2022)

WuXi Biologics (Cayman) Inc.(SEHK:2269) dropped from S&P Global 1200

Investor sentiment deteriorates as stock falls 17%

WuXi Biologics (Cayman) Inc. to Report Q4, 2023 Results on Mar 26, 2024

Investor sentiment deteriorates as stock falls 16%

WuXi Biologics Successfully Completes First 1,6000L Manufacturing Run in Ireland

Investor sentiment deteriorates as stock falls 21%

WuXi Biologics Launches WuXia ADCC PLUS™ for the Development and Manufacturing of Afucosylated Antibodies that Elicit Enhanced ADCC Effect

WuXi Biologics Receives U.S. Patent for Proprietary Bispecific Antibody Technology Platform WuXiBody™

Investor sentiment improves as stock rises 16%

WuXi Biologics (Cayman) Inc. Announces Executive Changes, Effective March 31, 2024

WuXi Biologics (Cayman) Inc. (SEHK:2269) commences an Equity Buyback Plan for 424,841,177 shares, representing 10% of its issued share capital, under the authorization approved on June 27, 2023.

New major risk - Share price stability

Investor sentiment deteriorates as stock falls 32%

Wuxi Biologics Successfully Implements Fully Integrated Continuous Process with Breakthrough Productivity of 6 g/L/Day At Pilot Scale

Board Member recently sold €2.9m worth of stock

Now 21% undervalued

WuXi Biologics Launches New High-Productivity Bioprocessing Platform WuXiUI™ for Cost-Effective Commercial Manufacturing and Desirable Product Quality

First half 2023 earnings released: EPS: CN¥0.55 (vs CN¥0.61 in 1H 2022)

Wuxi Biologics (Cayman) Inc. Announces Executive Changes

WuXi Biologics (Cayman) Inc. to Report First Half, 2023 Results on Aug 23, 2023

Investor sentiment deteriorates as stock falls 22%

Now 23% undervalued after recent price drop

CEO & Executive Director recently sold €1.5m worth of stock

WuXi Biologics (Cayman) Inc., Annual General Meeting, Jun 15, 2023

WuXi Biologics (Cayman) Inc. Announces Demise of Ning Zhao, Non-Executive Director, Member of Remuneration Committee and Member of Environmental, Social and Governance Committee

WuXi Biologics (Cayman) Inc. Announces Board and Board Committee Changes

Now 21% undervalued after recent price drop

Full year 2022 earnings released: EPS: CN¥1.06 (vs CN¥0.81 in FY 2021)

WuXi Biologics (Cayman) Inc. to Report Fiscal Year 2022 Results on Mar 22, 2023

Investor sentiment improved over the past week

WuXi Biologics (Cayman) Inc. Announces Demise of Teh-Ming Walter Kwauk, Independent Non-Executive Director, the Chairman of the Audit Committee of the Company and A Member of the Nomination Committee of the Company

CEO & Executive Director recently sold €740k worth of stock

Wuxi Biologics (Cayman) Inc. Announces Appointments to Strategy Committee

Less than half of directors are independent

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

WuXi Biologics (Cayman) Inc. (SEHK:2269) commences an Equity Buyback Plan for 425,926,547 shares, representing 10% of its issued share capital, under the authorization approved on June 10, 2022.

WuXi Biologics (Cayman) Inc. Receives Regulatory Approvals for Drug Substance and Drug Product Facilities from U.S. FDA and EMA

Investor sentiment deteriorated over the past week

First half 2022 earnings released: EPS: CN¥0 (vs CN¥0.44 in 1H 2021)

WuXi Biologics (Cayman) Inc. Appoints Weichang Zhou as Member of the Strategy Committee

Now 21% undervalued

WuXi Biologics (Cayman) Inc. Provides Earnings Guidance for the Six Months Ended June 30, 2022

Now 21% undervalued

CEO & Executive Director recently sold €2.1m worth of stock

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Full year 2021 earnings released: EPS: CN¥0.81 (vs CN¥0.43 in FY 2020)

Less than half of directors are independent

Investor sentiment deteriorated over the past week

Less than half of directors are independent

Gelir ve Gider Dağılımı

Kazanç ve Gelir Geçmişi

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi